logo
Plus   Neg
Share
Email

Mortgage Rates Drop

Mortgage rates, or interest rates on home loans, dropped amid the ongoing coronavirus pandemic, according to mortgage provider Freddie Mac (FMCC.OB).

Releasing the results of its primary mortgage market survey, Freddie Mac said that the 30-year fixed-rate mortgage or FRM averaged 3.50 percent for the week ending March 26, 2019, down from 3.65 last week. A year ago at this time, the average rate was 4.06 percent.

The 15-year FRM this week averaged 2.92 percent, down from 3.06 percent last week. A year ago at this time, the 15-year FRM averaged 3.57 percent.

The 5-year Treasury-indexed hybrid adjustable-rate mortgage or ARM averaged 3.34 percent, up from 3.11 percent last week. It was 3.75 percent a year ago.

"The Federal Reserve's swift and significant efforts to stabilize the market were much needed and helped mortgage rates drop for the first time in three weeks," said Sam Khater, Freddie Mac's Chief Economist. "Similar to other segments of the economy, real estate demand is softening. However, the combination of the Fed's actions and pending economic stimulus will provide substantial support to the mortgage markets."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
Follow RTT